Openbookopenbook
Equity
Bounce Mobile Systems Inc(BNCM)
USD --+0.00%
Reward60Moderate
Risk71High
📊75%Data
Revenue down 16% YoY
BNCM
+0.0 · +0.00%
USD · PINK
Bounce Mobile Systems Inc | Financial Services
Balanced
Market Cap:14.00M
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
71
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BNCM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bounce Mobile Systems Inc?

engages in the development and distribution of pharmaceutical and healthcare products in Asia and the Philippines.

BNCM · Verdict

Solid reward · high risk

BNCM's standout is growth; volatility and cash flow weigh on the picture.

Based on 88% data coverage

BNCM · Verdict

What’s working & what to watch

Strengths 1

  • Growth68/100

    Revenue +1076.6% CAGR

Watchouts 3

  • Volatility5/100

    Weak vs peers

  • Cash flow35/100

    2% free-cash-flow margin

  • Balance sheet44/100

    Interest covered 2.0×

Model-based scoring. For information only — not financial advice.

What is Bounce Mobile Systems Inc?

engages in the development and distribution of pharmaceutical and healthcare products in Asia and the Philippines. It also engages in the development, distribution, and trading of medical supplies, equipment, pharmaceutical products, and food supplements. The company is listed on the PINK in USA, operating in the Financial Services sector, with a market capitalisation of 14.00M, and a P/E ratio of 0.3x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Performance tied to macro conditions — sensitive to interest rate cycles.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorFinancial Services
Market Cap14.00M
P/E Ratio0.3182
Dividend YieldN/A
52 Week High0.0123
52 Week Low0.004
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding2B
No. of Employees149
IndustryAsset Management
ExchangePINK
Beta2.578
CurrencyUSD
Websitedelexpharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.